uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Wärnberg, Fredrik
Alternative names
Publications (10 of 50) Show all publications
Wärnberg, F., Garmo, H., Folkvaljon, Y., Holmberg, L., Karlsson, P., Sandelin, K., . . . Bremer, T. (2018). Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS). Paper presented at San Antonio Breast Cancer Symposium, DEC 05-09, 2017, San Antonio, TX. Cancer Research, 78(4)
Open this publication in new window or tab >>Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)
Show others...
2018 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 78, no 4Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-351602 (URN)10.1158/1538-7445.SABCS17-GS5-08 (DOI)000425489400036 ()
Conference
San Antonio Breast Cancer Symposium, DEC 05-09, 2017, San Antonio, TX
Note

Wos title: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

Supplement: S

Meeting Abstract: GS5-08

Available from: 2018-05-29 Created: 2018-05-29 Last updated: 2018-09-12Bibliographically approved
Wärnberg, M., Karakatsanis, A., Abdsaleh, S. & Wärnberg, F. (2018). Abstract P3-01-11: Discoloration after injection of super paramagnetic iron oxide (SPIO) for sentinel node biopsy. A long term qualitative follow-up study. Paper presented at San Antonio Breast Cancer Symposium, DEC 05-09, 2017, San Antonio, TX. Cancer Research, 78(4)
Open this publication in new window or tab >>Abstract P3-01-11: Discoloration after injection of super paramagnetic iron oxide (SPIO) for sentinel node biopsy. A long term qualitative follow-up study
2018 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 78, no 4Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-351603 (URN)10.1158/1538-7445.SABCS17-P3-01-11 (DOI)000425489400340 ()
Conference
San Antonio Breast Cancer Symposium, DEC 05-09, 2017, San Antonio, TX
Note

Wos title: Discoloration after injection of super paramagnetic iron oxide (SPIO) for sentinel node biopsy. A long term qualitative follow-up study

Available from: 2018-05-29 Created: 2018-05-29 Last updated: 2018-05-29Bibliographically approved
Wadsten, C., Wärnberg, F., Tolockiene, E., Hartman, J., Fredriksson, I., Garmo, H. & Sund, M. (2018). Biomarkers in DCIS associated with breast cancer death. Paper presented at 11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN. European Journal of Cancer, 92, S67-S68
Open this publication in new window or tab >>Biomarkers in DCIS associated with breast cancer death
Show others...
2018 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 92, p. S67-S68Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
ELSEVIER SCI LTD, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-357180 (URN)000429103100169 ()
Conference
11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN
Available from: 2018-08-14 Created: 2018-08-14 Last updated: 2018-08-14Bibliographically approved
Plate, S., Emilsson, L., Söderberg, M., Brandberg, Y. & Wärnberg, F. (2018). High experienced continuity in breast cancer care is associated with high health related quality of life. BMC Health Services Research, 18, Article ID 127.
Open this publication in new window or tab >>High experienced continuity in breast cancer care is associated with high health related quality of life
Show others...
2018 (English)In: BMC Health Services Research, ISSN 1472-6963, E-ISSN 1472-6963, Vol. 18, article id 127Article in journal (Refereed) Published
Abstract [en]

Background: High experienced continuity is known to be associated with lower needs for supportive care and most likely higher quality of life. On this background, the aim of this study was to investigate if patient-experienced continuity of care was associated with health-related quality of life (HRQoL) in breast cancer patients treated at two different-sized breast cancer units.

Methods: In 2016, two questionnaires, "Statements on experienced continuity of care" and "The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)", were sent out to patients diagnosed between 2011 and 2014 at two different-sized breast cancer units in Sweden. Lead times and other data reflecting medical quality were collected from the patients' medical records and from the National Swedish Breast Cancer Quality Register.

Results: Of 356 eligible patients, 231 (65%) answered the questionnaires, of whom 218 patients were included in the analyses. A statistically significant association was found between high experienced continuity and high global HRQoL (p = 0.03). Continuity was higher at the smaller unit, while no major differences between the units were found regarding medical quality or lead times.

Conclusion: The study found that high experienced continuity and HRQoL was strongly associated. A statistically significant higher continuity of care was found at the smaller unit, in line with what was expected. The absence of clinically relevant differences in lead times and medical quality may indicate that continuity could be achieved without loss of quality.

Place, publisher, year, edition, pages
BIOMED CENTRAL LTD, 2018
Keywords
Continuity of care, Health-related quality of life, HRQoL, Breast cancer, Patient reported outcome
National Category
Nursing
Identifiers
urn:nbn:se:uu:diva-349349 (URN)10.1186/s12913-018-2925-0 (DOI)000425530200003 ()29458376 (PubMedID)
Available from: 2018-04-27 Created: 2018-04-27 Last updated: 2018-04-27Bibliographically approved
Sjöström, M., Staaf, J., Eden, P., Wärnberg, F., Bergh, J., Malmström, P., . . . Fredriksson, I. (2018). Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Research, 20, Article ID 64.
Open this publication in new window or tab >>Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
Show others...
2018 (English)In: Breast Cancer Research, ISSN 1465-5411, E-ISSN 1465-542X, Vol. 20, article id 64Article in journal (Refereed) Published
Abstract [en]

Background: Adjuvant radiotherapy is the standard of care after breast-conserving surgery for primary breast cancer, despite a majority of patients being over-or under-treated. In contrast to adjuvant endocrine therapy and chemotherapy, no diagnostic tests are in clinical use that can stratify patients for adjuvant radiotherapy. This study presents the development and validation of a targeted gene expression assay to predict the risk of ipsilateral breast tumor recurrence and response to adjuvant radiotherapy after breast-conserving surgery in primary breast cancer.

Methods: Fresh-frozen primary tumors from 336 patients radically (clear margins) operated on with breast-conserving surgery with or without radiotherapy were collected. Patients were split into a discovery cohort (N = 172) and a validation cohort (N = 164). Genes predicting ipsilateral breast tumor recurrence in an Illumina HT12 v4 whole transcriptome analysis were combined with genes identified in the literature (248 genes in total) to develop a targeted radiosensitivity assay on the Nanostring nCounter platform. Single-sample predictors for ipsilateral breast tumor recurrence based on a k-top scoring pairs algorithm were trained, stratified for estrogen receptor (ER) status and radiotherapy. Two previously published profiles, the radiosensitivity signature of Speers et al., and the 10-gene signature of Eschrich et al., were also included in the targeted panel.

Results: Derived single-sample predictors were prognostic for ipsilateral breast tumor recurrence in radiotherapy-treated ER+ patients (AUC 0.67, p = 0.01), ER+ patients without radiotherapy (AUC = 0.89, p = 0.02), and radiotherapy-treated ER-patients (AUC = 0.78, p < 0.001). Among ER+ patients, radiotherapy had an excellent effect on tumors classified as radiosensitive (p < 0.001), while radiotherapy had no effect on tumors classified as radioresistant (p=0.36) and there was a high risk of ipsilateral breast tumor recurrence (55% at 10 years). Our single-sample predictors developed in ER+ tumors and the radiosensitivity signature correlated with proliferation, while single-sample predictors developed in ER-tumors correlated with immune response. The 10-gene signature negatively correlated with both proliferation and immune response.

Conclusions: Our targeted single-sample predictors were prognostic for ipsilateral breast tumor recurrence and have the potential to stratify patients for adjuvant radiotherapy. The correlation of models with biology may explain the different performance in subgroups of breast cancer.

Place, publisher, year, edition, pages
BMC, 2018
Keywords
Breast cancer, Gene expression, Radiotherapy, Radiosensitivity, Radioresistance, Ipsilateral breast tumor recurrence, Local recurrence, Nanostring, nCounter
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-360186 (URN)10.1186/s13058-018-0978-y (DOI)000437333200001 ()29973242 (PubMedID)
Funder
The Breast Cancer FoundationSwedish Cancer SocietyRegion SkåneMagnus Bergvall FoundationGunnar Nilsson Cancer FoundationCancer and Allergy FoundationKing Gustaf V Jubilee FundThe Cancer Society in StockholmMarianne and Marcus Wallenberg Foundation
Available from: 2018-09-13 Created: 2018-09-13 Last updated: 2018-09-13Bibliographically approved
Karakatsanis, A., Tasoulis, M. K., Wärnberg, F., Nilsson, G. & MacNeill, F. (2018). Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. Paper presented at Annual Meeting of the Swedish-Surgical-Society, AUG, 2017, Jonkoping, SWEDEN. British Journal of Surgery, 105(5), 469-481
Open this publication in new window or tab >>Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer
Show others...
2018 (English)In: British Journal of Surgery, ISSN 0007-1323, E-ISSN 1365-2168, Vol. 105, no 5, p. 469-481Article in journal (Refereed) Published
Abstract [en]

Background

Neoadjuvant therapy (NAT) for operable breast cancer may facilitate more breast-conserving surgery (BCS). It seems, however, that this benefit is not being realized fully.

Methods

A systematic review of the literature was performed. RCTs were included. The criteria for inclusion were: documentation of surgical assessment before and after NAT, surgery performed (BCS or mastectomy), and clinical and pathological responses.

Results

A total of 1452 patients from seven RCTs met the inclusion criteria. After NAT, the feasibilityof BCS increased from 43⋅3to60⋅4 per cent (P < 0⋅001), but BCS was performed in only 51⋅8percent(P = 0⋅04). Only 31 per cent of patients who became eligible for BCS (assessed on clinical response)underwent BCS (pooled rate ratio 0⋅31, 95 per cent c.i. 0⋅22 to 0⋅44; P < 0⋅001). Of the mastectomycandidates who achieved a pathological complete response after NAT, only 41 per cent underwent BCS(pooled rate ratio 0⋅41, 0⋅23 to 0⋅74; P = 0⋅003). The main factors that influenced the decision not to shiftto BCS, even though it was feasible, were clinical assessment before NAT, multicentricity and tumoursize at presentation.

Conclusion

Breast surgery performed after NAT does not reflect tumour response, resulting in potentially unnecessary radical surgery, especially mastectomy. The barriers to maximizing the surgical benefits of NAT need to be better understood and explored. Still unnecessary mastectomies

National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-354236 (URN)10.1002/bjs.10807 (DOI)000428846100003 ()29603132 (PubMedID)
Conference
Annual Meeting of the Swedish-Surgical-Society, AUG, 2017, Jonkoping, SWEDEN
Available from: 2018-06-29 Created: 2018-06-29 Last updated: 2018-06-29Bibliographically approved
Wadsten, C., Wennstig, A.-K., Garmo, H., Nilsson, G., Blomqvist, C., Holmberg, L., . . . Sund, M. (2018). Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. Breast Cancer Research and Treatment, 171(1), 95-101
Open this publication in new window or tab >>Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ
Show others...
2018 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 171, no 1, p. 95-101Article in journal (Refereed) Published
Abstract [en]

The use of adjuvant radiotherapy (RT) in the management of ductal carcinoma in situ (DCIS) is increasing. Left-sided breast irradiation may involve exposure of the heart to ionising radiation, increasing the risk of ischemic heart disease (IHD). We examined the incidence of IHD in a population-based cohort of women with DCIS. The Breast Cancer DataBase Sweden (BCBase) cohort includes women registered with invasive and in situ breast cancers 1992-2012 and age-matched women without a history of breast cancer. In this analysis, 6270 women with DCIS and a comparison cohort of 31,257 women were included. Through linkage with population-based registers, data on comorbidity, socioeconomic status and incidence of IHD was obtained. Hazard ratios (HR) for IHD with 95% confidence intervals (CI) were analysed. Median follow-up time was 8.8 years. The risk of IHD was not increased for women with DCIS versus women in the comparison cohort (HR 0.93; 95% CI 0.82-1.06), after treatment with radiotherapy versus surgery alone (HR 0.77; 95% CI 0.60-0.98) or when analysing RT by laterality (HR 0.85; 95% CI 0.53-1.37 for left-sided versus right-sided RT). The risk of IHD was lower for women with DCIS allocated to RT compared to non-irradiated women and to the comparison cohort, probably due to patient selection. Comparison of RT by laterality did not show any over-risk for irradiation of the left breast.

Place, publisher, year, edition, pages
SPRINGER, 2018
Keywords
Ductal carcinoma in situ, Radiotherapy, Ischemic heart disease
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-361504 (URN)10.1007/s10549-018-4803-1 (DOI)000438656200010 ()29730730 (PubMedID)
Funder
The Breast Cancer FoundationVästerbotten County Council
Available from: 2018-09-25 Created: 2018-09-25 Last updated: 2018-09-25Bibliographically approved
Obondo, C., Karakatsanis, A., Eriksson, S., Hersi, A. F., Pistiolis, L., Abdsaleh, S., . . . Wärnberg, F. (2018). SentiDose - A dose optimizing study with SiennaXP, a superparamagnetic iron oxide for sentinel node detection. Paper presented at 11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN. European Journal of Cancer, 92, S79-S79
Open this publication in new window or tab >>SentiDose - A dose optimizing study with SiennaXP, a superparamagnetic iron oxide for sentinel node detection
Show others...
2018 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 92, p. S79-S79Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
ELSEVIER SCI LTD, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-357179 (URN)000429103100206 ()
Conference
11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN
Available from: 2018-08-14 Created: 2018-08-14 Last updated: 2018-08-14Bibliographically approved
Wadsten, C., Garmo, H., Fredriksson, I., Sund, M. & Wärnberg, F. (2017). DCIS and the risk of breast cancer death - A case control study. Paper presented at San Antonio Breast Cancer Symposium, DEC 06-10, 2016, San Antonio, TX. Cancer Research, 77
Open this publication in new window or tab >>DCIS and the risk of breast cancer death - A case control study
Show others...
2017 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 77Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Sundsvall Hosp, Sundsvall, Sweden. Umea Univ, Umea, Sweden. Uppsala Univ, Uppsala, Sweden. Uppsala Orebro, Reg Canc Ctr, Uppsala, Sweden. Kings Coll London, Canc Epidemiol & Populat Hlth, London, England. Karolinska Inst, Solna, Sweden.: AMER ASSOC CANCER RESEARCH, 2017
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-320981 (URN)10.1158/1538-7445.SABCS16-P3-17-03 (DOI)000397999001245 ()
Conference
San Antonio Breast Cancer Symposium, DEC 06-10, 2016, San Antonio, TX
Available from: 2017-04-27 Created: 2017-04-27 Last updated: 2017-04-27Bibliographically approved
Zhou, W., Sollie, T., Tot, T., Blomqvist, C., Abdsaleh, S., Liljegren, G. & Wärnberg, F. (2017). Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. International Journal of Breast Cancer, Article ID 4351319.
Open this publication in new window or tab >>Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort
Show others...
2017 (English)In: International Journal of Breast Cancer, ISSN 2090-3170, E-ISSN 2090-3189, article id 4351319Article in journal (Refereed) Published
Abstract [en]

Casting-type calcifications and a histopathological picture with cancer-filled duct-like structures have been presented as breast cancer with neoductgenesis. We correlated mammographic features and histopathological neoductgenesis with prognosis in a DCIS cohort with long follow-up. Mammographic features were classified into seven groups according to Tabar. Histopathological neoductgenesis was defined by concentration of ducts, lymphocyte infiltration, and periductal fibrosis. Endpoints were ipsilateral (IBE) in situ and invasive events. Casting-type calcifications and neoductgenesis were both related to high nuclear grade, ER-and PR-negativity, and HER2 overexpression but not to each other. Casting-type calcifications and neoductgenesis were both related to a nonsignificant lower risk of invasive IBE, HR 0.38 (0.13-1.08) and 0.82 (0.29-2.27), respectively, and the HR of an in situ IBE was 0.90 (0.41-1.95) and 1.60 (0.75-3.39), respectively. Casting-type calcifications could not be related to a worse prognosis in DCIS. We cannot explain why a more aggressive phenotype of DCIS did not correspond to a worse prognosis. Further studies on how the progression from in situ to invasive carcinoma is driven are needed.

Place, publisher, year, edition, pages
Hindawi Publishing Corporation, 2017
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-319323 (URN)10.1155/2017/4351319 (DOI)000394652400001 ()
Available from: 2017-04-10 Created: 2017-04-10 Last updated: 2017-11-29Bibliographically approved
Organisations

Search in DiVA

Show all publications